Cadonilimab clinical trials
Also written AK104.
How each study uses cadonilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cadonilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
172 studies that test it; most in 2023 (61); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 9 |
| 2021 | 6 |
| 2022 | 18 |
| 2023 | 61 |
| 2024 | 49 |
| 2025 | 15 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 45 · Other 128
Akeso (40) · Sun Yat-sen University (10) · Tianjin Medical University Cancer Institute and Hospital (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Fudan University (4) · West China Hospital (3) · Sichuan University (3) · The First Affiliated Hospital of Zhengzhou University (3)
Often tested with
Tested in the same studies.
Anlotinib (10) · Ivonescimab (8) · Lenvatinib (6) · Disitamab vedotin (5) · Paclitaxel (4) · Albumin-Bound Paclitaxel (2) · Docetaxel (2) · Dresbuxelimab (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 29, 5 in phase 3
Studies that test cadonilimab, phase 3 first.
- Nov 2026A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaPhase 3 · Akeso
- Dec 2026DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyPhase 2/3 · RemeGen Co., Ltd.
- Aug 2027Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Phase 3 · Sun Yat-sen University
- Oct 2027Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian CancerPhase 3 · Anhui Provincial Hospital
- Nov 2027A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaPhase 3 · Akeso
- Nov 2026A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCPhase 2 · Akeso
- Dec 2026Perioperative Cadonilimab (AK104) in Locally Advanced MSI-H/dMMR Gastric or Gastroesophageal Junction and Colorectal AdenocarcinomaPhase 2 · Peking University
- Dec 2026Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard TreatmentPhase 2 · Second Affiliated Hospital, School of Medicine, Zhejiang University
- Dec 2026AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerPhase 1/2 · Akeso
- Dec 2026Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRCNot applicable · Liu Huang
Studies
Open first, then newest update. How each study uses cadonilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 173
- Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot StudyNot yet recruitingEarly Phase 1Olivia Newton-John Cancer Research InstituteNCT07908147Written as Cadonilimab
- A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial CancerNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07900256Written as Cadonilimab
- Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian CancerRecruitingPhase 3Anhui Provincial HospitalNCT06542549Written as AK104
- A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal CancerNot yet recruitingPhase 2Summit TherapeuticsNCT07877194Written as Ivonescimab (dose level 1) combined with Cadonilimab
- FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)RecruitingPhase 3Fudan UniversityNCT07815834Written as Cadonilimab (AK104)
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingPhase 3AkesoNCT07700979Written as Cadonilimab
- A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07631000Written as Cadonilimab
- THIO and Cadonilimab in Resectable Hepatocellular CarcinomaRecruitingEarly Phase 1University of Texas Southwestern Medical CenterNCT07446257Written as Cadonilimab
- HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular CarcinomaRecruitingPhase 2Tongji HospitalNCT06187961Written as Cadonilimab
- A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.RecruitingPhase 1/2Shanghai Pharmaceuticals Holding Co., LtdNCT05944224Written as Cadonilimab
- Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal MetastasisRecruitingPhase 2Ruijin HospitalNCT06519591Written as Cadonilimab, LM-302, S-1, paclitaxel
- A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationPhase 1Peking University Cancer Hospital & InstituteNCT06424626Written as AK104+Axitinib
- A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male ParticipationsNot yet recruitingPhase 1AkesoNCT07619001Written as AK104 (New Site)
- Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial CarcinomaRecruitingPhase 2Shandong Cancer Hospital and InstituteNCT06532539Written as Cadonilimab
- Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerRecruitingPhase 3AkesoNCT07412613Written as Cadonilimab (AK104)
- Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard TreatmentRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05926700Written as Candonilimab
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308Written as cadonilimab
- Cadonilimab Combined With RT in LACC Patients Ineligible for CCRTNot yet recruitingPhase 2Ruijin HospitalNCT07450963Written as Cadonilimab
- A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 3AkesoNCT07449780Written as AK104(SC)
- Ligufalimab and Cadonilimab in Advanced Liver CancersRecruitingPhase 2University of Texas Southwestern Medical CenterNCT06789848Written as Cadonilimab
See all 173 studies that test cadonilimab →
Given beside what is tested · 16 — cadonilimab is usual care or a partner of the new treatment
- Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal MetastasisRecruitingPhase 1/2Guangzhou Medical UniversityNCT06762080Written as Cadonilimab (AK104)
- A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid TumorsRecruitingPhase 1AkesoNCT06929663Written as AK104 injection
- AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)RecruitingPhase 2Fudan UniversityNCT07544784Written as AK104 with radiotherapy
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.RecruitingPhase 2AkesoNCT07052253Written as AK104
- A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)RecruitingPhase 1/2AkesoNCT06530251Written as Cadonilimab
- IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT06654011Written as Cadonilimab
- A Study of Ivonescimab in First-Line ES-SCLCRecruitingPhase 2AkesoNCT07245446Written as Cadonilimab
- A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 1/2AkesoNCT04982276Written as AK104
- AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic TherapyRecruitingPhase 2Fudan UniversityNCT06494995Written as Cadonilimab
- A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDACNot yet recruitingPhase 1AkesoNCT06913218Written as Cadonilimab
- A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic CancerRecruitingPhase 2AkesoNCT05859750Written as AK104
- Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ PatientsRecruitingPhase 1/2Zhejiang Cancer HospitalNCT06650332Written as cadonilimab
- Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary MetastasesRecruitingNot applicableSun Yat-sen UniversityNCT06265350Written as Cadonilimab
- Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2AkesoNCT05960955Written as Cadonilimab
- Cadonilimab With Chemotherapy in Treating Advanced Biliary CancerRecruitingPhase 2West China HospitalNCT05978609Written as Candonilimab
- A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104CompletedPhase 1Akesobio Australia Pty LtdNCT04349969Written as AK117+AK104
As the comparator · 1 — what is tested is compared with cadonilimab
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered2
Codes
What other systems call cadonilimab · ClinicalTrials.gg INT015265
- UNII (FDA) 6FYG1DS4NWCADONILIMABOne source FDA
- NCI Thesaurus C153379CadonilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6FYG1DS4NW | CADONILIMAB | One source FDA |
| NCI Thesaurus | C153379 | Cadonilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.